Testing a new drug for diabetic macular edema
Part of Eyes & vision, Hormones & metabolism clinical trials.
This trial tests a new medicine called PRO-169 for people with diabetic macular edema (swelling in the back of the eye caused by diabetes). The goal is to see if it is safe and how the body responds to it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have type 1 or type 2 diabetes.
- You have diabetic macular edema with central involvement (the swelling affects the center of your vision).
- You have a certain level of vision loss (between 20/32 and 20/320 on a standard eye chart).
- You are willing to use birth control if you are able to have children.
- You have not used certain eye treatments (like anti-VEGF injections or steroids) in the past 4 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (RO7823653) given as an eye injection for people with diabetic macular edema, a condition where swelling in the retina harms vision. It aims to see if the drug is safe and how the body processes it.
This trial tests an investigational drug called CU06-1004 for people with diabetic macular edema (swelling in the center of the retina caused by diabetes). It aims to see if the drug can improve vision and reduce swelling.
This study tests different doses of a new medicine (BI 3812465) injected into the eye to treat diabetic macular edema—swelling in the back of the eye caused by diabetes that can blur vision. The trial measures how safe the medicine is and how well patients tolerate it.
This trial tests an experimental medication (BI 1815368) given as an eye injection for people with diabetic macular edema, a condition where fluid builds up in the center of the retina and blurs vision. The study aims to see if this new treatment can reduce swelling and improve vision.
This Phase 3 study compares a new eye injection (RC28-E) with the standard treatment (aflibercept) for diabetic macular edema, which is swelling in the central retina that affects vision. It aims to see whether the new treatment works as well and is safe.
This Phase 1 trial tests MS-553 to see how it works and how safely it can be given to people with diabetic retinopathy causing central macular swelling (macular edema). You may be considered if your vision and eye scan results match, and if you can follow frequent study visits.
Hear when a new Immunogenicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.